NATAP UPDATE

[streamline569]

"Rates of response in subgroups with host or baseline characteristics that have been historically associated with poor treatment outcome were also examined. Overall, 69% of patients with a high viral load (≥800,000 IU per milliliter) had a sustained virologic response. Among those with an extended rapid virologic response, HCV RNA levels at baseline were not a predictor of a sustained virologic response, which was achieved in nearly 90% of patients with high viral load. Similarly, genotype subtype (1a vs. 1b) did not affect the treatment outcome, either in the overall population or among randomly assigned patients (Table 2). In all, 63% of patients with bridging fibrosis or cirrhosis had a sustained virologic response. Among patients with an extended rapid virologic response and bridging fibrosis or cirrhosis, rates of sustained virologic response were 82% in the T12PR24 group and 88% in the T12PR48 group (Table 2). This difference was not significant. Overall, 74% of white patients versus 60% of black patients had a sustained virologic response (P=0.02) (Table 2). Neither race nor ethnic group was associated with any decrease in the rate of sustained virologic response among the patients who had had an extended rapid virologic response; no significant differences were observed between the two randomized subgroups."

[yodennis]

These are some significantly positive outcomes (especially for those of us with cirrhosis). Thanks for taking the time to post this. d

[streamline569]

http://www.clinicaloptions.com/Hepatitis/Conference Coverage/AASLD 2010/Tracks/HCV Treatment/Capsules/LB2.aspx?lg=print

[Willy50]

Anytime a trial or article is "quoted" it is very much recommended/ required to post a link to the article.  Titles are also much appreciated.  : )

The authors want it and your readers here will appreciate it as well.

willy